Nature's Sunshine Products Inc. Common Stock (NATR)
Stock · NASDAQ · Health Care
$12.64as of 10/16/2026
Price chart
Active signals
NATR Signal Track Record
How signals performed across all stocks →What NATR's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 42 | +1.1% | 60% | August 6, 2026 |
| Bollinger Band Breakout | 23 | +1.4% | 57% | June 29, 2026 |
| Bollinger Band Breakdown | 20 | +0.9% | 50% | September 15, 2026 |
| 200-Day Moving Average TouchActive now | 11 | -0.9% | 45% | June 29, 2026 |
| Any 20-session window (baseline) | 0.0% | 50% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About NATR
Nature's Sunshine Products, Inc., a natural health and wellness company, manufactures and sells nutritional and personal care products in Asia, Europe, North America, Latin America, and internationally. The company distributes general health products related to blood sugar support, bone health, cellular health, cognitive function, joint health, mood, sexual health, sleep, sports and energy, and vision; and immune pro…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 806
- Website
- www.naturessunshine.com/
Fundamentals
- 1-day range
- $12.8$13.18
- Market cap
- $357.68M
- P/E (trailing)
- 12.66
- P/E (forward)
- 10.59
- EPS (trailing)
- $1.00
- Dividend yield
- —
- Beta
- 0.81
- Avg. volume
- 166.9K
- Ex-dividend date
- March 26, 2021
- Dividend pay date
- April 9, 2021
Forecasts
2 analyst ratings
Nature's Sunshine Products Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- NATRNature's Sunshine Products Inc. Common Stock$12.64▲ 0.00%Market cap $357.68MP/E 12.66$12.8$28.14
- ZNTLZentalis Pharmaceuticals Inc. Common Stock$2.13▼ 4.91%Market cap $355.93MP/E —$1.21$6.95
- DMACDiaMedica Therapeutics Inc. Common Stock$7.57▼ 5.85%Market cap $364.79MP/E —$5.25$10.42
- LYELLyell Immunopharma Inc. Common Stock$8.12▼ 0.85%Market cap $348.21MP/E —$7.2$45
- PRLDPrelude Therapeutics Incorporated Common Stock$3.26▼ 1.81%Market cap $372.74MP/E —$1.16$6.83
- UPBUpstream Bio Inc. Common Stock$2.76▼ 18.10%Market cap $373.87MP/E —$3.29$33.68
- CATXPerspective Therapeutics Inc. Common Stock$2.17▼ 7.26%Market cap $338.72MP/E —$1.96$6.16
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| NATR Nature's Sunshine Products Inc. Common Stock | $357.68M | 12.66 | $12.64 | ▲ 0.00% | $12.8$28.14 |
| ZNTL Zentalis Pharmaceuticals Inc. Common Stock | $355.93M | — | $2.13 | ▼ 4.91% | $1.21$6.95 |
| DMAC DiaMedica Therapeutics Inc. Common Stock | $364.79M | — | $7.57 | ▼ 5.85% | $5.25$10.42 |
| LYEL Lyell Immunopharma Inc. Common Stock | $348.21M | — | $8.12 | ▼ 0.85% | $7.2$45 |
| PRLD Prelude Therapeutics Incorporated Common Stock | $372.74M | — | $3.26 | ▼ 1.81% | $1.16$6.83 |
| UPB Upstream Bio Inc. Common Stock | $373.87M | — | $2.76 | ▼ 18.10% | $3.29$33.68 |
| CATX Perspective Therapeutics Inc. Common Stock | $338.72M | — | $2.17 | ▼ 7.26% | $1.96$6.16 |
P/E shows — for peers not currently carrying a live signal of their own.
Insider Activity
Insider Actions →- PRESCOTT GROUP CAPITAL MANAGEMENT, L.L.C. · August 10, 2026 · Buy16.9K @ $15.8
- PRESCOTT GROUP CAPITAL MANAGEMENT, L.L.C. · August 10, 2026 · Buy10.0K @ $16.01
- PRESCOTT GROUP CAPITAL MANAGEMENT, L.L.C. · August 10, 2026 · Buy13.1K @ $15.78
- PRESCOTT GROUP CAPITAL MANAGEMENT, L.L.C. · August 10, 2026 · Buy876 @ $15.64
- PRESCOTT GROUP CAPITAL MANAGEMENT, L.L.C. · August 7, 2026 · Buy10.0K @ $16.46
- PRESCOTT GROUP CAPITAL MANAGEMENT, L.L.C. · August 7, 2026 · Buy20.0K @ $16.55
- PRESCOTT GROUP CAPITAL MANAGEMENT, L.L.C. · August 7, 2026 · Buy30.0K @ $16.68
- PRESCOTT GROUP CAPITAL MANAGEMENT, L.L.C. · August 7, 2026 · Buy5.0K @ $16.62
- PRESCOTT GROUP CAPITAL MANAGEMENT, L.L.C. · August 7, 2026 · Buy1.0K @ $16.48
- PRESCOTT GROUP CAPITAL MANAGEMENT, L.L.C. · August 6, 2026 · Buy2.5K @ $16.75
- PRESCOTT GROUP CAPITAL MANAGEMENT, L.L.C. · August 6, 2026 · Buy2.0K @ $16.35
- Kevin R. Herbert · June 12, 2026 · Sale866 @ $20.75
- Kevin R. Herbert · June 12, 2026 · Sale1.1K @ $20.63
- Bryant J. Yates · June 5, 2026 · Sale12.0K @ $19.9
- Daniel C. Norman · June 1, 2026 · Sale9.7K @ $20.64
Institutional Ownership
March 31, 2026
- Total shares held
- 14.92M
- Total value held
- $337.92M
- Institutional holders
- 148
- Unknown2.47M
- Unknown1.78M
- Unknown1.06M
- Unknown895.4K
- Unknown691.5K
- Unknown657.8K
- Unknown596.8K
- Unknown574.8K
- Unknown531.9K
- Unknown372.5K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 29, 2026
Nature's Sunshine Q2 Earnings Reviewed Against Peers
A recent analysis compared Nature's Sunshine's second-quarter results with other personal care companies. This review helps investors understand how the stock performed relative to its sector during that period. The company currently trades with a trailing P/E ratio of 13.3, while analysts maintain an average price target of $30.50.
Nature's Sunshine Q2 Earnings Reviewed Against Peers. A recent analysis compared Nature's Sunshine's second-quarter results with other personal care companies. This review helps investors understand how the stock performed relative to its sector during that period. The company currently trades with a trailing P/E ratio of 13.3, while analysts maintain an average price target of $30.50.